- Home
- COCP
as 10-17-2024 4:00pm EST
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 18.2M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 18.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.33 - $3.10 | Next Earning Date: | 11-11-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cocrystal Pharma Inc. News
COCP Breaking Stock News: Dive into COCP Ticker-Specific Updates for Smart Investing
GlobeNewswire
22 days ago
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
GlobeNewswire
2 months ago
Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences
Zacks Small Cap Research
2 months ago
COCP: Topline Results from Phase 2a Study of CC-42344 in 2H24…
ACCESSWIRE
2 months ago
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
GlobeNewswire
2 months ago
Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Zacks Small Cap Research
3 months ago
COCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated…
GlobeNewswire
3 months ago
Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
Zacks Small Cap Research
4 months ago
COCP: CC-42344 Shows In Vitro Activity Against Avian Influenza A (H5N1)…
Compare COCP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COCP Cocrystal Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.